^
    Back
    Association details:
    Biomarker:HER-2 underexpression
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Zejula (niraparib) (PARP inhibitor) +
    Jivadco (trastuzumab duocarmazine) (HER2-targeted antibody-drug conjugate, DNA replication inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 4043: SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs)

    Published date:
    05/15/2020
    Excerpt:
    ...niraparib and olaparib act in synergy with SYD985 in killing human HER2-expressing tumor cells in vitro, both in high HER2 (BT-474, AU-565, UACC-893) and low HER2 (NIH:OVCAR-3; TOV-112D) expressing cells.
    DOI:
    10.1158/1538-7445.AM2020-4043